ArkeaBio Raises $15M Series A Led by AgriZeroNZ to Scale Methane-Reducing Cattle Vaccine

ArkeaBio Secures $15M Series A

ArkeaBio, a global agricultural bioscience company, has raised $15 million in Series A funding. The round was led by AgriZeroNZ, with participation from Breakthrough Energy Ventures. The funding closed on September 30, 2026.

What ArkeaBio Does

ArkeaBio is developing a safe, cost-effective vaccine to reduce methane emissions from cattle worldwide. According to the company, it is the first to successfully demonstrate a proof-of-concept vaccine. The company describes its solution as the safest and most cost-effective way to reduce greenhouse gas emissions in agriculture, and the only one that can be quickly and sustainably scaled to reach all the world's cattle.

The company positions its vaccine as a singular, scalable solution that delivers value to farmers, brands, consumers, and the climate.

The Funding Round

• Round type: Series A
• Amount: $15,000,000 USD
• Date: September 30, 2026
• Lead investor: AgriZeroNZ
• Participating investors: Breakthrough Energy Ventures, AgriZeroNZ

Why This Matters for Acquisition

ArkeaBio operates at the intersection of agricultural bioscience and climate technology. Its proof-of-concept vaccine targets methane emissions from cattle, a significant source of agricultural greenhouse gases. The involvement of AgriZeroNZ, a climate-focused investor, and Breakthrough Energy Ventures signals strong strategic interest in scalable climate solutions for agriculture.

For acquirers in agtech, climate tech, or animal health, ArkeaBio represents a differentiated asset: a vaccine platform with a demonstrated proof of concept and a stated path to global scale. The company's focus on cost-effectiveness and scalability aligns with the needs of farmers and food brands facing increasing pressure to reduce emissions.

About the Investors

AgriZeroNZ led the round. Breakthrough Energy Ventures also participated. Both investors are known for backing climate and agricultural innovation, though further details on their specific roles or prior investments are not provided in the funding announcement.

Looking Ahead

The Series A funding will likely support ArkeaBio's continued development and scaling of its methane-reducing vaccine. As the company advances from proof of concept toward broader deployment, it may attract additional interest from strategic partners in the agricultural and climate sectors.

For acquisition-oriented readers, ArkeaBio's technology and investor syndicate make it a company to watch in the growing market for sustainable agriculture solutions.